by Torrico F, Gascon J, Ortiz L, Alonso-Vega C, Pinazo MJ, Schijman A, Almeida IC, Alves F, Strub-Wourgaft N, Ribeiro I. The Lancet Infectious Diseases 2018, doi 10.1016/S1473-3099(17)30538-8.
Summary: Chagas disease is a major neglected vector-borne disease. In this study, we investigated the safety and efficacy of three oral E1224 (fosravuconazole) regimens and benznidazole versus placebo in adult chronic indeterminate Chagas disease. E1224 displayed a transient, suppressive effect on parasite clearance, whereas benznidazole showed early and sustained efficacy until 12 months of follow-up. Despite PCR limitations, the results support increased diagnosis and access to benznidazole standard regimen, and provide a development roadmap for novel benznidazole regimens in monotherapy and in combinations with E1224. Presentation of the results at the 2013 ASTMH event
Click here to read the article / PDF / Accepted pre-publication manuscript